RedLeaf Biologics

RedLeaf Biologics is a biotechnology company that produces patented, plant-based bioactive ingredients derived from a rare, non-GMO red sorghum varietal. By leveraging a discovery where a specific sorghum plant acts as a botanical bioreactor to produce high concentrations of polyphenols, the company has developed a proprietary water-based extraction process. Their flagship product, ReDaxin, is a phenolic-rich extract designed to offer high stability, solubility, and purity for use across dietary supplements, functional foods, beverages, and cosmetics. The company maintains a fully U.S.-based, vertically integrated supply chain, partnering with local farmers to cultivate the sorghum through traditional and regenerative row-crop methods.

These ingredients are primarily used by product formulators to address consumer demand for clean-label, plant-derived health solutions, particularly in areas such as sports nutrition, inflammation management, oxidative stress protection, and immune health. ReDaxin has been supported by human clinical studies demonstrating its efficacy in improving strength recovery and reducing muscle soreness after intense exercise. As a Kentucky-based firm founded in 2015, the company emphasizes sustainable, traceable production standards, including self-affirmed GRAS status, and works with various industry partners to incorporate their bioactive compounds into diverse consumer delivery formats, ranging from capsules and powders to gummies and functional drinks.